Latest News
-
Wednesday - January 13, 2021
Not intended for U.S. and UK Media - Virtual Bayer Pharma Media Day:
Bayer transforms pharma business through breakthrough innovation in healthcare
Emerging leadership in field of cell and gene therapies / Accelerating breakthrough innovation for patients / Innovation in field of digital health solutions to become key pillar of Bayer’s pharmaceutical business empowering patients with Integrated Care offerings / Promising development portfolio with more than 50 projects in clinical development phases » more
-
Tuesday - January 12, 2021
Gene Therapy Leader Katherine High Joins AskBio as President, Therapeutics » more
-
Tuesday - January 12, 2021
Not intended for U.S. and UK Media
U.S. FDA grants Priority Review to New Drug Application for finerenone to treat patients with chronic kidney disease and type 2 diabetes » more
-
Monday - January 11, 2021
Accelerating the Transformation of Bayer:
Supervisory Board of Bayer AG appoints Sarena Lin to Board of Management as Chief Transformation and Talent Officer » more
-
Thursday - January 7, 2021
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Bayer issues new senior bonds with a volume of 4 billion euros
Issuance of four tranches with maturities between 4 and 15 years was substantially oversubscribed » more
-
Thursday - January 7, 2021
BlueRock Therapeutics in Collaboration with Memorial Sloan Kettering Cancer Center Receives IND Clearance for DA01 in Parkinson’s Disease » more
-
Thursday - January 7, 2021
CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV
Companies enter into a collaboration and services agreement / Bayer to support CureVac in numerous areas, including development and supply of CVnCoV / CureVac benefits from Bayer´s expertise and established infrastructure / Plan to facilitate the supply of several hundred million doses » more
-
Wednesday - January 6, 2021
Leaps by Bayer leads USD 105 million Series B financing in Senti Bio to develop next-generation cell and gene therapies using advanced gene circuit technology platform
Senti Bio’s gene circuit technology platform has the potential to optimize cell and gene therapies across delivery modalities and therapeutic areas / Proceeds to support platform expansion and advance multiple allogeneic CAR-NK cell therapy pipeline candidates for difficult-to-treat cancers, including acute myeloid leukemia and hepatocellular carcinoma » more
-
Monday - December 21, 2020
Bayer sells a facility at its Wuppertal site to WuXi Biologics
Companies to also enter into long-term sublease agreement and service contract / Buyer planning to use facility to produce COVID-19 vaccine and other biologics » more
-
Wednesday - December 16, 2020
Bayer Steps Up Its Commitments to Support Smallholder Farmers in Asia
Through the expansion of the Better Life Farming Alliance to Bangladesh and Indonesia, Bayer and its partners will provide more smallholders with better access to innovative and sustainable agricultural solutions, and increased farm incomes / In 2021, the “Better Farms, Better Lives” initiative will extend to China’s Hubei Province, providing 200,000 farmers in the region with immediate assistance in the form of crop protection inputs, market access and support for health and safety needs. Currently, the program is helping more than 1.5 million farmers in 17 countries sustain their livelihoods during the Covid-19 pandemic » more
-
Tuesday - December 8, 2020
CDP rating:
Bayer leads in sustainability
Bayer receives the highest CDP score for its activities in the climate and water categories / Important progress has been made in terms of climate protection this year: Conversion to green electricity has been started, CO2 market has been developed for farmers / Confirmation of the company’s high commitment to sustainability » more
-
Monday - December 7, 2020
Not intended for U.S. and UK Media
Bayer and Atara Biotherapeutics enter strategic collaboration for next generation, mesothelin-targeted CAR-T cell therapies for solid tumors
Agreement is fundamental element of Bayer’s new Cell & Gene Therapy strategy / Bayer to enter CAR-T cell therapy space and expand oncology development pipeline with groundbreaking technology / Recognizes the leading position of Atara’s technology platform in allogeneic cell therapy / Partnership will focus on the next generation, off-the-shelf T-cell immunotherapy ATA3271 for treatment of high mesothelin-expressing tumors / Atara to receive upfront payment of USD 60 million, and up to a total of USD 610 million for development, regulatory and commercialization milestones, plus tiered royalties up to low double-digit percentage of net sales » more
-
Wednesday - December 2, 2020
Bayer establishes Cell and Gene Therapy Platform to accelerate pharmaceutical innovation
Cell and Gene Therapy Platform (C& GT) to drive groundbreaking science delivering breakthrough innovative treatments for patients / New Platform will steer strategically and orchestrate all activities along the value chain / Bayer’s C& GT pipeline already comprises five advanced assets and over fifteen preclinical candidates / Acquisition of Asklepios Biopharmaceutical successfully closed on December 1, 2020 / Wolfram Carius appointed Head of Bayer’s new C& GT Platform » more
-
Tuesday - December 1, 2020
Not intended for U.S. and UK Media
Bayer and Blackford Analysis to Collaborate on Integration of AI Solutions in Medical Imaging Workflow
Partners will establish new platform delivering centralized access to digital and AI applications throughout medical imaging workflow / Bayer to expand its AI capabilities and accelerates innovation in medical imaging together with health-technology partners / AI in medical imaging increases efficiency and reduces diagnostic errors with the potential to positively impact disease management and patient outcomes » more
-
Tuesday - December 1, 2020
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL
Bayer announces placement of Elanco shares for gross proceeds of 1.6 billion U.S. dollars at completion » more
-
Monday - November 30, 2020
Bayer introduces Fludora® Co-Max to combat resistant mosquitoes and control vector-borne diseases worldwide
Innovative combination space spray solution demonstrates improved efficacy in controlling Aedes mosquitoes - vectors of arboviral diseases » more
-
Wednesday - November 18, 2020
BlockApps Launches Agribusiness Blockchain Network ‘TraceHarvest’ Following Success with Bayer
BlockApps’ Ethereum-based TraceHarvest Network enhances food quality, safety and sustainability by bringing supply chain efficiencies, transparency, compliance and stewardship to agricultural products » more
-
Wednesday - November 18, 2020
Bayer initiates new G4A Digital Health Partnerships Program
Focus on fostering development of integrated healthcare solutions in fields of cardiometabolic and renal diseases, oncology, and women’s health / Germany’s Federal Minister of Health Jens Spahn to give keynote at the virtual digital health forum “G4A Agents of Change” at 5pm CET/11am EST today » more
-
Tuesday - November 17, 2020
Bayer Acquires Majority Stake in Care/of
Deal deepens Bayer’s capabilities in the personalized healthcare and nutritionals space » more
-
Tuesday - November 17, 2020
Not intended for U.S. and UK Media - Late-Breaking Data from subgroup analysis of Phase III FIDELIO-DKD study presented at the American Heart Association (AHA) Scientific Sessions 2020
Finerenone showed consistent benefits on cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes with or without history of cardiovascular disease
In the FIDELIO-DKD Phase III study among patients with chronic kidney disease and type 2 diabetes, overall finerenone significantly lowered the combined risk of cardiovascular events, with comparable treatment efficacy for patients with or without history of cardiovascular disease / People with chronic kidney disease and type 2 diabetes are three times more likely to die from a cardiovascular-related cause than those with type 2 diabetes alone / Finerenone is a first-in-class investigational non-steroidal, selective mineralocorticoid receptor (MR) antagonist that specifically addresses MR overactivation, a key driver of disease progression » more
Copyright @ Bayer AG